OpenAlex
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant
Work
Year: 2016
Type: article
Abstract: The phase III Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial-Extended Criteria Donors Trial (BENEFIT-EXT) study compared more or less intensive belatacept... more
Cites: 36
Cited by: 34
Related to: 10
FWCI: 2.59
Citation percentile (by year/subfield): 91.84
Field: Medicine
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $4,300